Compare Haleon plc American Depositary Shares (Each representing two Ordinary Shares) (HLN) vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Haleon plc American Depositary Shares (Each representing two Ordinary Shares) vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) — how do they compare? Haleon plc American Depositary Shares (Each representing two Ordinary Shares) trades at $9.88 (market cap $42.21B), while RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $37.8 (market cap $63.89B). The key difference: RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) is the larger of the two by market cap, and RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| HLN | RELX | |
|---|---|---|
Market Cap | $42.21B | $63.89B |
Volume | 13,841,864 | 2,760,502 |
Sector | Health | Industrials |
52-Week High | $11.27 | $46.80 |
52-Week Low | $8.70 | $27.73 |
Typical Hold Time | 3 Days | — |
Enterprise Value | $52.02B | $75.40B |
Dividend Yield | 2.05% | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Haleon (HLN) trades at $9.44, down 0.63% today, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with $11.03B revenue, 14.55% net margin, and consistent earnings beats in recent quarters. Recent business developments include successful shelf space negotiations with major retailers and growth from weight-loss drug side-effect products.
The outlook remains positive with 75% analyst buy ratings and improving cash flow projections for 2026. Key opportunities include market share gains and margin expansion, while risks involve competitive pressures and potential margin compression. The stock presents a balanced risk-reward profile for investors seeking exposure to consumer healthcare.
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
Haleon is a consumer healthcare company offering over-the-counter medicines, oral health products, vitamins, and wellness brands.
Read more on HLN →About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →
